|View printer-friendly version|
|Covance Enters into Strategic Technology Agreement with GSK|
Leverages Covance’s Xcellerate® Informatics Technology Across GSK’s Global Clinical Trials Portfolio
“We are thrilled to have the opportunity to collaborate with GSK,” said
A key component of the technology licensed by GSK is Xcellerate® Monitoring, Covance’s comprehensive implementation of risk-based monitoring, which enables assessment and mitigation of risk at the study, site and patient level. It also allows sponsors to strategically guide site monitoring resources and build quality and efficiency into their clinical trials, from commencement to completion. As part of the agreement, Covance will support GSK with implementation, starting in the first half of 2018.
Xcellerate® is an award-winning technology solution that uses advanced data integration, analytics and visualization capabilities to improve patient safety, data quality and protocol compliance throughout the clinical development process. The Xcellerate® suite offers timely, secure, integrated and contextualized access to clinical-trial data to reduce the cost, time and risks associated with clinical studies and enable full transparency and oversight of study conduct and performance.
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.
This press release contains forward-looking statements about the
Company’s future operations. Each of the forward-looking statements is
subject to change based on various important factors, including without
limitation, competitive actions in the marketplace, and adverse actions
of governmental and other third-party payers. Actual results could
differ materially from those suggested by these forward-looking
statements. The Company has no obligation to provide any updates to
these forward-looking statements even if its expectations change.
Further information on potential factors that could affect operating and
financial results is included in the Company’s Form 10-K for the year
|Print Page | E-mail Page | RSS Feeds | E-mail Alerts | IR Contacts | Tear Sheet|